Contact : +1 (888) 308-1808

/

PepGen’s DMD Exon 51 Skipping Program On Clinical Hold In US

PepGen has received a clinical hold notice from the FDA regarding its Investigational New Drug (IND) application in Duchenne amenable to skipping exon 51, and will be unable to initiate their Phase 2 CONNECT2-EDO51 trial in the U.S, until that is resolved.  PepGen is currently conducting an open-label CONNECT1-EDO51 multiple ascending dose study in Canada, and the CONNECT2 trial is already open in the United Kingdom. 

Read the full press release HERE

The post PepGen’s DMD Exon 51 Skipping Program On Clinical Hold In US appeared first on CureDuchenne.

Leave a Reply

Your email address will not be published. Required fields are marked *